ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Pfizer's Maraviroc, Novel Medicine For HIV, Significantly Reduces Viral Load, In Combination Therapy Across Range Of Treatment-Experienced Patients
At this week's major
HIV/AIDS research meeting, Pfizer presented pivotal data of its
experimental medicine, maraviroc, which tackles HIV in an entirely new way.
A 24 week analysis showed that approximately twice as many patients
receiving maraviroc with an optimized background regimen achieved
undetectable virus in the blood than if an optimized regimen was given
alone.
The new data, presented at the 14th Conference on Retroviruses and
Opportunistic Infections (CROI), support the accelerated United States and
European regulatory review of maraviroc as a treatment for patients
infected with HIV that is "CCR5 tropic," -- enters immune cells by a
receptor known as CCR5. A test confirms whether a patient is infected with
CCR5-tropic HIV.
In addition, patients receiving maraviroc and an optimized regimen saw
an increase in CD4 cells nearly twice that seen in those receiving
optimized regimen alone. Adverse events in the group receiving maraviroc
plus an optimized regimen were similar to those receiving an optimized
regimen alone when adjusted for duration of exposure.
"Data from the two identical studies are remarkably consistent and
demonstrate significant decreases in viral load and increases in CD4 cells
when maraviroc is added to the standard optimized treatment regimen," said
Dr. Howard Mayer, Pfizer's global clinical lead for the maraviroc
development program, who also presented the trial results.
If approved, maraviroc would be the first new oral class of HIV
medicines in more than a decade, meeting the urgent need of HIV patients
for new drug classes. Discovered by Pfizer scientists in 1997, maraviroc is
an oral medicine that blocks viral entry to human cells. Rather than
fighting HIV inside white blood cells, it prevents the virus from entering
uninfected cells by blocking its predominant entry route, the CCR5
co-receptor.
Recently, regulatory authorities in the U.S., Europe and Canada granted
accelerated review of maraviroc. Accelerated reviews are granted to
potential medicines that if approved have the potential to fulfill an unmet
medical need. Pfizer is also in the process of submitting marketing
applications around the world to make maraviroc available globally. The
U.S. Food and Drug Administration's Antiviral Drugs Advisory Committee will
discuss maraviroc in April.
Pfizer is committed to bringing meaningful improvement to the lives of
people living with HIV/AIDS and those at risk around the world. This
commitment is embodied in Pfizer's products, partnerships, pipeline and
philanthropy. Current initiatives include the U.S. Southern States HIV/AIDS
Prevention Initiative; the building of the Infectious Disease Institute in
Kampala, Uganda; the Pfizer Global Health Fellows Program; and the
Diflucan(R) Partnership Program.
For more information on these and other Pfizer initiatives, go to
http://www.pfizer.com.
Background on data supporting maraviroc
The latest results were analyzed at 24 weeks from the ongoing
multicenter, double-blind, placebo-controlled phase 2b/3 MOTIVATE trials
(Maraviroc Plus Optimized Therapy in Viremic Antiretroviral Treatment
Experienced Patients).
In both studies, approximately twice as many patients treated with
maraviroc plus optimized background therapy (OBT) for either once or twice
daily dosing achieved undetectable viral loads (
Pfizer's Maraviroc, roman medicament pentru HIV, reduce semnificativ a încãrcãturii virale, în asociere în întreaga gamã de tratament, pacienþii care au experienþã - Pfizer's Maraviroc, Novel Medicine For HIV, Significantly Reduces Viral Load, In Combination Therapy Across Range Of Treatment-Experienced Patients - articole medicale engleza - startsanatate